Evidence map›Paper›PMID 28264682›Full record

ArticleBMC biotechnology2017

An engineered food-grade Lactococcus lactis strain for production and delivery of heat-labile enterotoxin B subunit to mucosal sites.

Nan Sun, Rongguang Zhang, Guangcai Duan, Xiaoyan Peng, Chen Wang, Qingtang Fan, Shuaiyin Chen, Yuanlin Xi

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Cells · 2019
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nan SunDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China.
Rongguang ZhangDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China. zrg@zzu.edu.cn.
Guangcai DuanDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China. gcduan@zzu.edu.cn.
Xiaoyan PengDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China.
Chen WangDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China.
Qingtang FanDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China.
Shuaiyin ChenDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China.
Yuanlin XiDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China.
Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent researches have been focusing on mucosal immune adjuvants, which play the key roles in mucosal immunization and have become the limitation for non-injected vaccine development. Escherichia coli heat-labile enterotoxin B subunit (LTB) was regarded as a promising mucosal adjuvant for its nontoxicity and potent activity. LTB preparation issues have always been recurring, in part owing to that the recombinant LTB expressed by E. coli does not act as its native form.

resultsWe constructed an engineered Lactococcus lactis strain using a food-grade expression system. The LTB secreted by the engineered strain was detected in the culture supernatant, constituting 10.3% of the supernatant proteins, and recognized by mouse anti-LTB antibodies. The engineered strain, co-administered orally to SPF BALB/c mice with a H. pylori vaccine candidate expressing Lpp20 antigen, could significantly enhance the Lpp20-induced mucosal SIgA antibody responses against H. pylori.

conclusionsThis is the first report that LTB was efficiently produced and delivered via using a food-grade lactococcal expression system, which offers a novel production and utilization mode of this crucial mucosal adjuvant. The engineered L. lactis strain secreting LTB has considerable potential for oral vaccine formulation owing to its outstanding safety, adjuvant activity and high-level production.

Indexed as

ProbioticsAnimalsBacterial VaccinesEnterotoxinsLactobacillusMiceMice, Inbred C57BLMouth MucosaProtein EngineeringSpecies SpecificityTemperatureBacterial Vaccinesenterotoxin B, staphylococcalEnterotoxinsFood-gradeHelicobactor pyloriLactococcus lactisLpp20LTBOral vaccine

Identifiers

PMID28264682
PMCPMC5339977
OpenAlexW2593507097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.